Background. According to recent studies, amyloid‐β (Aβ) isoforms as cerebrospinal fluid
(CSF) biomarkers have remarkable predictive value for cognitive decline in the early stages …

Amyloid-β, tau pathology, and biomarkers of neurodegeneration make up the core
diagnostic biomarkers of Alzheimer disease (AD). However, these proteins represent only a …

Background Core biomarkers for Alzheimer's disease (AD), such as Aβ42 and tau, have
demonstrated high prognostic accuracy but do not fully capture the complex …

Background: Alzheimer's disease (AD) is diagnosed based on a clinical evaluation as well
as analyses of classical biomarkers: Aß42, total tau (t-tau), and phosphorylated tau (p-tau) in …

Background Clinicopathological studies suggest that Alzheimer's disease (AD) pathology
begins∼ 10–15 years before the resulting cognitive impairment draws medical attention …

Introduction The dynamic range of cerebrospinal fluid (CSF) amyloid β (Aβ1–42)
measurement does not parallel to cognitive changes in Alzheimer's disease (AD) and …

Alzheimer's disease (AD) is the most prevalent form of dementia among elderly people
worldwide. Cerebrospinal fluid (CSF) is the optimal fluid source for AD biomarkers, while …

The pathology of Alzheimer's disease (AD) begins years prior to clinical diagnosis. The
development of antecedent biomarkers that indicate the presence of AD pathology and …

Background Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied
during the 'preclinical'stage (pathology present with cognition intact) before severe neuronal …

Background: Cerebrospinal fluid (CSF) biomarkers are used to diagnose Alzheimer disease
(AD), especially in atypical clinical presentations. No consensus currently exists regarding …